| Vasculitis |
1 |
1 |
| Clinical Guidelines |
0 |
0.79 |
| Remission |
0 |
0.32 |
| Biologic Therapy |
0 |
0.31 |
| Antineoplastic Drug |
0 |
0.25 |
| Monoclonal Antibody |
0 |
0.25 |
| Biopsy |
0 |
0.16 |
| Ultrasonography |
0 |
0.16 |
| Cerebrovascular Accident |
0 |
0.15 |
| Health Care Reform |
0 |
0.15 |
| Scleroderma |
0 |
0.15 |
| Artery |
0 |
0.13 |
| California |
0 |
0.13 |
| Clinical Research |
0 |
0.13 |
| Hospital |
0 |
0.13 |
| Outpatient Clinic |
0 |
0.13 |
| Surgery |
0 |
0.13 |
| Giant Cell Arteritis |
0 |
0.8 |
| Polyarteritis Nodosa |
0 |
0.75 |
| Takayasu Arteritis |
0 |
0.7 |
| Renal Failure |
0 |
0.09 |
| Glucocorticoid |
0 |
0.06 |
| Grant |
0 |
0.06 |
| Granulomatosis |
0 |
0.06 |
| Immunosuppressive Therapy |
0 |
0.06 |
| Aneurysm |
0 |
0.04 |
| Anxiety Disorder |
0 |
0.04 |
| Social Determinants of Health |
0 |
0.04 |
| Tumor Necrosis Factor-Alpha |
0 |
0.04 |
| Abdomen |
0 |
0.03 |
| Anxiety |
0 |
0.03 |
| Child |
0 |
0.03 |
| Europe |
0 |
0.03 |
| Glomerulonephritis |
0 |
0.03 |
| Health Care Quality, Access, and Evaluation |
0 |
0.03 |
| Kawasaki Disease |
0 |
0.03 |
| Microscopic Polyangiitis |
0 |
0.03 |
| New York |
0 |
0.03 |
| Plasma |
0 |
0.03 |
| Renal Disease |
0 |
0.03 |
| Tumor |
0 |
0.03 |